Efficacy and safety of Guipi Decoction combined with conventional Western medicine in the treatment of insomnia with deficiency of heart and spleen: a meta-analysis

Background. Modified Yunu-Jian (mYJ), a Chinese medicine (CM) formula, is thought to clear heat and nourish yin. Clinically, it is often used to treat oral inflammation. However, its efficacy remains controversial. Methods. The study aims to evaluate the efficacy and safety of mYJ for treating patients with periodontitis. We searched electronic databases (PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure, Wanfang database, VIP database, and CBM) from inception to December 2020. Only randomized controlled trials investigating modified Yunu-Jian, with or without other medications, against controlled intervention in the treatment of patients diagnosed with periodontitis were included. Both Review Manager 5.3 and Stata 15.0 software were used to analyze the data. The Cochrane Collaborations risk of bias tool was used to assess the quality of the methods. Results. Thirteen clinical trials, involving 1179 participants, were included in our investigation. The results showed that the combination of mYJ with western medicine improved the total effective rate compared with western medicine alone (RR = 1.17, 95% CI (1.12, 1.23), P < 0.00001). The sensitivity analysis and Harbord’s test ( P = 0.255) both showed that the results were statistically robust. Moreover, the periodontal indexes (GI, SBI, PLI, and PD; P < 0.00001) of patients with periodontitis were also significantly improved after receiving the combined therapy. No serious adverse reactions were observed in the experimental groups. Conclusions. Evidence from the meta-analysis suggested that mYJ appeared to be effective and relatively safe for treating periodontitis. Because of the low quality of the methods used in the included RCTs, further studies with larger sample sizes and well-designed models are required to confirm our findings.

Download Full-text

Efficacy and safety of Danggui Buxue Decoction in combination with western medicine treatment of anemia for renal anemia: a systematic review and meta-analysis

Annals of Translational Medicine ◽

10.21037/atm.2017.01.17 ◽

2017 ◽

Vol 5 (6) ◽

pp. 136-136 ◽

Cited By ~ 7

Author(s):

Ming-Ming Zhao ◽

Yu Zhang ◽

Liu-Sheng Li ◽

Zi-Kai Yu ◽

Bo Li

Keyword(s):

Systematic Review ◽

Western Medicine ◽

Meta Analysis ◽

Renal Anemia ◽

Efficacy And Safety ◽

Danggui Buxue Decoction

Download Full-text

Efficacy and Safety of Acupuncture with Western Medicine for Rheumatoid Arthritis: A Systematic Review and Meta-analysis

Acupuncture & Electro-Therapeutics Research ◽

10.3727/036012921x16237619666076 ◽

2021 ◽

Author(s):

Xinhui Huo ◽

Lili Liang ◽

Xia Ding ◽

Angshaer Bihazi ◽

Haiyan Xu

Keyword(s):

Western Medicine ◽

Analogue Scale ◽

English Language ◽

Meta Analysis ◽

Chinese Language ◽

Efficacy And Safety ◽

C Reactive Protein ◽

Reactive Protein ◽

Randomized Controlled ◽

Erythrocyte Sedimentation

Objectives: In the present study, we assessed the therapeutic qualities of the combination of acupuncture with Western medicine to determine further lines of clinical research. Methods: We searched English-language databases and Chinese-language databases for randomized controlled trials (RCTs) published up to February 2020. Two reviewers performed a meta-analysis of the efficacy and toxicity of the use of acupuncture with Western medicine for RA measured by a visual analogue scale (VAS), rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). Results: In total, 9 RCTs involving 698 patients were included for analysis. VAS, ESR, CRP, and RF were all shown to favor the combination of acupuncture with Western medicine compared to Western medicine alone. ST36 (Zusanli), EX-UE9 (Baxie), Ll11 (Quchi), GB34 (Yanglingquan), TE14 (Jianliao) and TE4(Yangchi) were frequently used in 9 clinical trials. Conclusion: Treatment using acupuncture with Western medicine was associated with higher efficacy and lower risks than treatment with Western medicine alone. ST36 (Zusanli), EX-UE9 (Baxie), Ll11 (Quchi), GB34 (Yanglingquan), TE14 (Jianliao) and TE4 (Yangchi) were frequently used in treatment of RA and had been verified with effect in clinical practice

Download Full-text

Efficacy and Safety of Integrated Traditional Chinese Medicine and Western Medicine on the Treatment of Rheumatoid Arthritis: A Meta-Analysis

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2020/4348709 ◽

2020 ◽

Vol 2020 ◽

pp. 1-15 ◽

Cited By ~ 3

Author(s):

Qi Xing ◽

Ling Fu ◽

Zhichao Yu ◽

Xueping Zhou

Keyword(s):

Rheumatoid Arthritis ◽

Chinese Medicine ◽

Treatment Group ◽

Traditional Chinese Medicine ◽

Western Medicine ◽

Meta Analysis ◽

Cochrane Library ◽

Integrative Treatment ◽

Efficacy And Safety ◽

Integrated Therapy

Objective. Integrated therapy of traditional Chinese medicine (TCM) and Western medicine (WM) has gradually been applied to the treatment of rheumatoid arthritis (RA). Recently published studies have provided a wealth of data and information about the effectiveness of combination treatments, but high-quality evidence-based meta-analysis on this issue is not available yet. This study was conducted to compare and evaluate the efficacy and safety of the integrated therapy for RA. Methods. PubMed, EMBASE, and the Cochrane Library were searched up to January 2020. Randomized controlled trials (RCTs) that compared the efficacy and safety of integrative TCM-WM with WM alone for RA were included. The outcome measures contained therapeutic effects (TEs), tender joint count (TJC), swollen joint count (SJC), duration of morning stiffness (DMS), grip strength (GS), disease activity score in 28 joints (DAS28), rheumatoid factor (RF), anti-cyclic peptide containing citrulline (anti-CCP), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and adverse events (AEs) to assess the efficacy and safety of different treatments. Results. A total of 20 RCTs with 2269 patients met the inclusion criteria. TCM used in these studies included Chinese herbal decoctions and tablets or capsules made from herbs and their extracts, while WM included disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), and glucocorticoids (GC). Compared with patients receiving WM treatment alone, patients with integrative TCM-WM treatment showed better TEs (OR = 3.03, 95% CI [2.36, 3.88]). The integrative treatment group showed reductions in TJC (MD = −1.17, 95% CI [−2.12, −0.21]), SJC (MD = −0.87, 95% CI [−1.85, 0.10]), DMS (SMD = −0.69, 95% CI [−0.98, −0.41]), DAS28 (MD = −0.43, 95% CI [−0.57, −0.29]), RF (SMD = −0.59, 95% CI [−0.91, −0.27]), anti-CCP (SMD = −0.21, 95% CI [−0.36, −0.06]), ESR (MD = −8.36, 95% CI [−12.60, −4.12]), and CRP (MD = −6.73, 95% CI [−9.38, −4.08]), and increment in GS (SMD = 0.12, 95% CI [−0.63, 0.87]). AEs, especially gastrointestinal disorders, abnormal liver function, leukopenia, skin allergies and rashes, headaches and dizziness, and alopecia, significantly decreased (OR = 0.37, 95% CI [0.29, 0.47]) in the integrative treatment group. Conclusions. The findings of this meta-analysis indicate that integrative TCM-WM could obtain effective and safe results in the treatment of RA. Using TCM as an adjunctive therapy in RA has great prospects for further development.

Download Full-text

Efficacy and Safety of Shengmai Injection for Chronic Heart Failure: A Systematic Review of Randomized Controlled Trials

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2020/9571627 ◽

2020 ◽

Vol 2020 ◽

pp. 1-10

Author(s):

Yanping Wang ◽

Xu Zhou ◽

Xiaofan Chen ◽

Fei Wang ◽

Weifeng Zhu ◽

...

Keyword(s):

Heart Failure ◽

High Risk ◽

Chronic Heart Failure ◽

Western Medicine ◽

Meta Analysis ◽

Risk Of Bias ◽

Controlled Trials ◽

Efficacy And Safety ◽

Shengmai Injection ◽

Randomized Controlled

Background. Shengmai injection (SMI) is made from purified ginseng, Radix Ophiopogonis, and Schisandra chinensis. It has cardiotonic effects and is clinically used for the adjuvant treatment of chronic heart failure (CHF). However, its efficacy and safety are uncertain. The purpose of this study was to systematically evaluate the existing efficacy and safety evidence in randomized controlled trials (RCTs) that studied SMI for the treatment of CHF. Methods. PubMed, Embase, Cochrane Library, clinicaltrials.gov, CNKI, Wanfang, VIP, and CBM databases were searched up to September 10, 2019. RCTs that compared basic Western medicine treatment with SMI + basic Western medicine were included. The Cochrane Collaboration Risk of Bias Tool was used to assess the risk of bias in the RCTs. The meta-analysis used the random effects model; the mean difference (MD) and 95% confidence intervals (CIs) were combined using the inverse variance method, and the Mantel–Haenszel method was used to combine the relative risk (RR) and 95% CIs. Heterogeneity was assessed using I2 and Q tests, and the source of heterogeneity was explored by analyzing three preset subgroup hypotheses. Results. A total of 20 RCTs were included (n = 1562), with a moderate-to-high risk of bias. The meta-analysis showed that, compared with Western medicine alone, SMI adjuvant therapy significantly improved cardiac function indicators, including left ventricular ejection fraction (MD 6.8%, 95% CI 4.68 to 8.91), stroke volume (MD 9.81 ml, 95% CI 5.67 to 13.96), cardiac output (MD 0.96 L/min, 95% CI 0.66 to 1.25), and cardiac index (MD 0.53 L/min, 95% CI 0.36 to 0.70); heterogeneity was generally high among these outcomes. Compared with the controls, patients receiving SMI adjuvant therapy also had a higher response to treatment (RR 2.89, 95% CI 2.10 to 3.99; I2 = 0%), a greater decrease in brain natriuretic peptide levels (MD −284.66 ng/l, 95% CI −353.73 to −215.59, I2 = 0%), and a greater increase in six‐minute walk test performance (MD 70.67 m, 95% CI 22.92 to 118.42; I2 = 84%). Nine studies reported mild adverse events, such as gastrointestinal reactions, and no serious adverse events were reported. Conclusion. Currently, available evidence indicates that SMI, as an adjuvant for basic Western medicine treatment, can improve the cardiac function of patients with CHF with good safety outcomes. Because of the high risk of bias among the included RCTs and the large heterogeneity of partial outcomes, the findings of this study must be verified by high-quality studies with large sample sizes.

Download Full-text